Piper Sandler analyst David Amsellem assumed coverage of AbbVie (ABBV) with an Overweight rating and $231 price target The ...

In July 2025, AbbVie announced top line results from one of two parallel studies of the Phase III UP-AA trial evaluating upadacitinib in alopecia areata (AA).

Packaged breads and refined grain products may increase the odds of developing IBD, while minimally processed fresh bread and ...

Royalty Pharma Plc (NASDAQ:RPRX) is one of the top most undervalued biotech stocks to buy now. In a report released on August 7, Terence Flynn from Morgan Stanley maintained a Buy rating on Royalty ...

Overview of the Market  The global Cystic Fibrosis Market is valued at USD 10.3 Billion in 2024 and is projected to reach a ...

JPMorgan (NYSE: JPM) told investors in a note Monday that Eli Lilly & Co. (NYSE: LLY) shares are its “top pick” among U.S.

Following a planned succession process, the Board of Directors of Gubra has appointed Markus Rohrwild as the new CEO of the ...

We read with interest the Correspondence by Zhiqi Yao and colleagues1 published in The Lancet Diabetes & Endocrinology, which ...

A daily dose of blarcamesine restored autophagy among patients with early Alzheimer’s disease, with improved outcomes through 192 weeks, according to an abstract presented at the Alzheimer’s ...

Currently exempt from US tariffs, pharmaceutical manufacturers fear steep surcharges, as promised by the US president on ...

Patients with moderate to severe and severe alopecia areata have a greater burden of comorbid atopic dermatitis than those with mild alopecia areata.

The pharmaceutical industry faces an innovation crisis with declining R&D productivity, rising costs, and regulatory challenges impacting drug development.